Immunovant Sciences GmbH

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

Phase 2

Not yet recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: IMVT-1402
Drug: Placebo

First Posted Date: 2024-12-31

Last Posted Date: 2024-12-31

Lead Sponsor: Immunovant Sciences GmbH

Target Recruit Count: 120

Registration Number: NCT06754462

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Phase 2

Recruiting

Conditions: Graves' Disease

Interventions: Drug: IMVT-1402
Drug: Placebo

First Posted Date: 2024-12-11

Last Posted Date: 2024-12-31

Lead Sponsor: Immunovant Sciences GmbH

Target Recruit Count: 240

Registration Number: NCT06727604

Locations: 🇺🇸
Site number - 1002, Austin, Texas, United States

A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease

Phase 2

Recruiting

Conditions: Graves Disease

Interventions: Drug: IMVT-1401 (batoclimab)

First Posted Date: 2023-06-18

Last Posted Date: 2023-09-05

Lead Sponsor: Immunovant Sciences GmbH

Target Recruit Count: 45

Registration Number: NCT05907668

Locations: 🇩🇪
Site Number - 6505, Mainz, Germany

To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

Phase 2

Active, not recruiting

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy

Interventions: Drug: Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly
Drug: Batoclimab 340 mg SC weekly
Drug: Placebo

First Posted Date: 2022-10-14

Last Posted Date: 2024-11-25

Lead Sponsor: Immunovant Sciences GmbH

Target Recruit Count: 277

Registration Number: NCT05581199

Locations: 🇷🇴
Site Number - 8403, Timişoara, Timis, Romania
🇷🇴
SIte Number - 8400, Constanta, Romania
🇷🇸
Site Number - 8501, Belgrade, Serbia

and more 113 locations

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Phase 3

Recruiting

Conditions: Thyroid Eye Disease

Interventions: Drug: Batoclimab
Drug: Placebo

First Posted Date: 2022-09-01

Last Posted Date: 2024-12-19

Lead Sponsor: Immunovant Sciences GmbH

Target Recruit Count: 100

Registration Number: NCT05524571

Locations: 🇺🇸
Site Number -1514, Torrance, California, United States
🇺🇸
Site Number -1510, Sarasota, Florida, United States
🇺🇸
Site Number - 1521, Seattle, Washington, United States

and more 40 locations

Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

Phase 3

Recruiting

Conditions: Thyroid Eye Disease

Interventions: Other: Observational cohort study
Drug: Batoclimab

First Posted Date: 2022-08-26

Last Posted Date: 2024-12-19

Lead Sponsor: Immunovant Sciences GmbH

Target Recruit Count: 180

Registration Number: NCT05517447

Locations: 🇱🇻
Site Number - 9302, Ventspils, Latvia
🇵🇷
Site Number - 1990, San Juan, Puerto Rico
🇸🇰
Site Number - 9200, Bratislava, Slovakia

and more 34 locations

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Phase 3

Recruiting

Conditions: Thyroid Eye Disease

Interventions: Drug: Placebo
Drug: Batoclimab

First Posted Date: 2022-08-26

Last Posted Date: 2024-12-19

Lead Sponsor: Immunovant Sciences GmbH

Target Recruit Count: 100

Registration Number: NCT05517421

Locations: 🇺🇸
Site Number - 1538, Port Charlotte, Florida, United States
🇬🇧
Site Number - 7311, London, United Kingdom
🇺🇸
Site Number - 1557, Beverly Hills, California, United States

and more 89 locations

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

Phase 3

Active, not recruiting

Conditions: Generalized Myasthenia Gravis

Interventions: Drug: Batoclimab 340 mg SC bi-weekly
Drug: Batoclimab 340 mg SC weekly
Drug: Batoclimab 680 mg SC weekly
Drug: Matching Placebo SC

First Posted Date: 2022-06-03

Last Posted Date: 2024-08-07

Lead Sponsor: Immunovant Sciences GmbH

Target Recruit Count: 240

Registration Number: NCT05403541

Locations: 🇺🇸
Site Number - 1028, Port Charlotte, Florida, United States
🇺🇸
Site Number -1016, Dallas, Texas, United States
🇨🇦
Site Number - 2002, Toronto, Ontario, Canada

and more 102 locations

To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).

Phase 2

Terminated

Conditions: Warm Autoimmune Hemolytic Anemia

Interventions: Drug: RVT-1401 680 mg/weekly
Drug: RVT-1401 340 mg/weekly

First Posted Date: 2020-02-05

Last Posted Date: 2022-07-28

Lead Sponsor: Immunovant Sciences GmbH

Target Recruit Count: 5

Registration Number: NCT04253236

Locations: 🇪🇸
Hospital Universitario Quirónsalud Madrid, Barcelona, Spain
🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
🇮🇱
Meir Medical Center, Kfar Saba, Israel

and more 18 locations

ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )

Phase 2

Terminated

Conditions: Graves' Ophthalmopathy (GO)

Interventions: Other: Placebo (Administered via subcutaneous injection)
Drug: RVT-1401 (Administered via subcutaneous injection)

First Posted Date: 2019-05-06

Last Posted Date: 2022-09-22

Lead Sponsor: Immunovant Sciences GmbH

Target Recruit Count: 65

Registration Number: NCT03938545

Locations: 🇩🇪
Universitat Duisburg-Essen, Duisburg, Germany
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇨🇦
University of British Columbia, Vancouver, British Columbia, Canada

and more 22 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy